CNTG.F Stock Overview
Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Centogene N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$0.55 |
| 52 Week Low | US$0.038 |
| Beta | -0.12 |
| 1 Month Change | -5.61% |
| 3 Month Change | 30.69% |
| 1 Year Change | -62.24% |
| 3 Year Change | -94.72% |
| 5 Year Change | -99.06% |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper
Aug 06
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Feb 16Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks
Dec 21Centogene GAAP EPS of -€0.28, revenue of €10.32M
Jul 15Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?
Nov 25Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?
Jun 29Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)
Apr 17Shareholder Returns
| CNTG.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 15.2% | -0.4% | 2.2% |
| 1Y | -62.2% | -9.6% | 8.2% |
Return vs Industry: CNTG.F underperformed the US Healthcare industry which returned -9.6% over the past year.
Return vs Market: CNTG.F underperformed the US Market which returned 8.2% over the past year.
Price Volatility
| CNTG.F volatility | |
|---|---|
| CNTG.F Average Weekly Movement | 28.8% |
| Healthcare Industry Average Movement | 7.7% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CNTG.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTG.F's weekly volatility has decreased from 55% to 29% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 384 | n/a | www.centogene.com |
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.
Centogene N.V. Fundamentals Summary
| CNTG.F fundamental statistics | |
|---|---|
| Market cap | US$5.07m |
| Earnings (TTM) | -US$40.24m |
| Revenue (TTM) | US$54.97m |
0.1x
P/S Ratio-0.1x
P/E RatioIs CNTG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTG.F income statement (TTM) | |
|---|---|
| Revenue | €48.54m |
| Cost of Revenue | €30.84m |
| Gross Profit | €17.70m |
| Other Expenses | €53.23m |
| Earnings | -€35.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 36.46% |
| Net Profit Margin | -73.21% |
| Debt/Equity Ratio | -260.1% |
How did CNTG.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 22:19 |
| End of Day Share Price | 2025/05/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Centogene N.V. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Sung Ji Nam | BTIG |
| Erin Wilson Wright | Credit Suisse |